Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease

Haematologica

Volumn 98, Issue 4, 2013, Pages 533-537

  Chakraborty, Rikhia ^a   Mahendravada, Aruna ^a   Perna, Serena K ^a   Rooney, Cliona M ^a   Heslop, Helen E ^a   Vera, Juan F ^a   Savoldo, Barbara ^a   Dotti, Gianpietro ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELL EXPANSION; CELL ISOLATION; CONTROLLED STUDY; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NORMAL HUMAN; REGULATORY T LYMPHOCYTE; SENESCENCE; XENOGRAFT;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD2; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; COST-BENEFIT ANALYSIS; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GRAFT VS HOST DISEASE; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HETEROLOGOUS;

EID: 84875668081     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.076430     Document Type: Article

References (17)

1. Zorn E, Kim HT, Lee SJ, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005;106(8):2903-11.
2. Wang X, Lu L, Jiang S. Regulatory T cells: customizing for the clinic. Sci Transl Med. 2011;3(83):83ps19.
3. Leslie M. Immunology. Regulatory T cells get their chance to shine. Science. 2011; 332(6033):1020-1.
4. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117(14):3921-8.
5. Hippen KL, Riley JL, June CH, Blazar BR. Clinical perspectives for regulatory T cells in transplantation tolerance. Semin Immunol. 2011;23(6):462-8.
6. Chakraborty R, Rooney C, Dotti G, Savoldo B. Changes in chemokine receptor expression of regulatory T cells after ex vivo culture. J Immunother. 2012;35(4):329-36.
7. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+ CD25+FoxP3+ regulatory T cells. Blood. 2005;105(12):4743-8.
8. Vera JF, Brenner LJ, Gerdemann U, et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010; 33(3):305-15.
9. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203(7):1701-11.
10. Miyao T, Floess S, Setoguchi R, et al. Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity. 2012;36(2):262-75.
11. van Rijn RS, Simonetti ER, Hagenbeek A, et al. A new xenograft model for graft-versushost disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/-gammac-/-double-mutant mice. Blood. 2003;102(7):2522-31.
12. Tresoldi E, Dell'Albani I, Stabilini A, et al. Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells. Haematologica. 2011;96(9):1357-65.
13. Baecher-Allan C, Hafler DA. Suppressor T cells in human diseases. J Exp Med. 2004; 200(3):273-6.
14. Hippen KL, Merkel SC, Schirm DK, et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs) with minimal loss of in vivo functional activity. Sci Transl Med. 2011;3(83):83ra41.
15. Zheng SG, Wang JH, Koss MN, Quismorio F Jr, Gray JD, Horwitz DA. CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-wwsuppress a stimulatory graft-versus-host disease with a lupuslike syndrome. J Immunol. 2004;172(3): 1531-9.
16. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumorinfiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003; 26(4):332-42.
17. Smith CA, Ng CY, Heslop HE, et al. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproleferative disease. J Hematother. 1995;4(2):73-9.